Telisotuzumab vedotin clinical trials
Also written ABBV-399.
How each study uses telisotuzumab vedotin is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the telisotuzumab vedotin studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 14 May 2025 · EMRELIS · BLA 761384 (FDA, Drugs@FDA)
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
9 studies that test it; most in 2018 (2)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2017 | 1 |
| 2018 | 2 |
| 2022 | 2 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 2
AbbVie (7) · SWOG Cancer Research Network (1) · Jonsson Comprehensive Cancer Center (1)
Often tested with
Tested in the same studies.
Osimertinib (1) · Cisplatin (1) · Carboplatin (1) · Pemetrexed (1)
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test telisotuzumab vedotin.
- Feb 2027Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung CancerPhase 2 · Jonsson Comprehensive Cancer Center
Studies
Open first, then newest update. How each study uses telisotuzumab vedotin is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 9
- A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)RecruitingPhase 3AbbVieNCT04928846Written as Telisotuzumab Vedotin
- A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)RecruitingPhase 2AbbVieNCT06568939Written as Telisotuzumab Vedotin
- Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung CancerRecruitingPhase 2Jonsson Comprehensive Cancer CenterNCT07323641Written as Telisotuzumab Vedotin
- Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung CancerActive, not recruitingPhase 2AbbVieNCT03539536Written as Telisotuzumab vedotin
- A Study to Assess Disease Activity of Intravenously (IV) Infused Telisotuzumab Vedotin in Adult Participants With Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)TerminatedPhase 2AbbVieNCT05513703Written as Telisotuzumab Vedotin
- A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid TumorsActive, not recruitingPhase 1AbbVieNCT02099058Written as Telisotuzumab vedotin
- Study of Intravenous Telisotuzumab Vedotin in Combination Osimertinib or Standard of Care Chemotherapy to Assess Change in Disease Activity in Adult Participants With Non-Small Cell Lung Cancer That Has a Mutation in the Epidermal Growth Factor Receptor Gene and That Overexpresses the c-Met ProteinWithdrawnPhase 3AbbVieNCT06093503Written as Telisotuzumab Vedotin
- Lung-MAP S1400K: c-MET PositiveCompletedPhase 2SWOG Cancer Research NetworkNCT03574753Written as ABBV-399
- A Study to Evaluate the Safety and Pharmacokinetics ABBV-399 in Japanese Participants With Solid TumorsCompletedPhase 1AbbVieNCT03311477Written as ABBV-399
Codes
What other systems call telisotuzumab vedotin · ClinicalTrials.gg INT000893
- MeSH (NLM) C000626235telisotuzumab vedotinConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 976X9VXC3ZTELISOTUZUMAB VEDOTINConfirmed FDA, NLM
- NCI Thesaurus C118571Telisotuzumab VedotinOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000626235 | telisotuzumab vedotin | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 976X9VXC3Z | TELISOTUZUMAB VEDOTIN | Confirmed FDA, NLM |
| NCI Thesaurus | C118571 | Telisotuzumab Vedotin | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.